Current and future health and economic impact of hepatitis C in Belgium

Acta Gastro-Enterologica Belgica

Volumn 77, Issue 2, 2014, Pages 285-290

  Vandijck, D ^a,b   Moreno, C ^c   Starkel P ^d   Van Damme, P ^e   Van Vlierberghe, H ^f   Hindman, S J ^g   Razavi, H ^g   Laleman, W ^h  

^a GHENT UNIVERSITY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Center for Disease Analysis   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; BELGIUM; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; MODELS, ECONOMETRIC; MONTE CARLO METHOD;

EID: 84905098792     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Razavi H., Waked I., Sarrazin C. et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J. Viral. Hepat., 2014, 21 Suppl 1: 34-59.
2. Bruggmann P., Berg T., Ovrehus A.L. et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J. Viral. Hepat., 2014, 21 Suppl 1: 5-33.
3. Wedemeyer H., Duberg A.S., Buti M. et al. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral. Hepat., 2014, 21 Suppl 1: 60-89.
4. McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, 361: 580-93.
5. Razavi H., Elkhoury A.C., Elbasha E. et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013, 57: 2164-70.
6. Economist Intelligence Unit. The silent pandemic: Tackling hepatitis C with policy innovation. Janssen Pharmaceutica NV, 2012.
7. Lang K., Weiner D.B. Immunotherapy for HCV infection: next steps. Expert. Rev. Vaccines, 2008, 7: 915-23.
8. Nevens F., Colle I., Michielsen P. et al. Resource use and cost of hepatitis C-related care. Eur. J. Gastroenterol. Hepatol., 2012, 24: 1191-8.
9. Schwierz C., Thiry N., Van de Sande S. et al. Economic Evaluation of Antiviral Treatment of Chronic Hepatitis B - Part 2. Report (electronic). Brussels: Belgian Health Care Knowledge Centre (KCE), 2011 Jun 14. Report No.: 157A.
10. Statistics Belgium. Consumer Price Indices: Price Index Since 1920 and Health Index Since 1994.2013 [cited: May 6, 2013] Available from: URL: http://statbel.fgov.be/en/statistics/figures/economy/consumer_price_index/
11. Fretz R., Negro F., Bruggmann P. et al. Hepatitis B and C in Switzerland-healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med. Wkly., 2013, 143: 0.
12. Gerkens S., Martin N., Thiry N., Hulstaert F. [Hepatitis C: Screening and Prevention] HEPATITIS C: SCREENING EN PREVENTIE. Belgian Health Care Knowledge Center (KCE), 2012.
13. Quoilin S., Hutse V., Vandenberghe H. et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur. J. Epidemiol., 2007, 22: 195-202.
14. Myers R.P., Krajden M., Bilodeau M. et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Canadian Journal of Gastroenterology & Hepatology, 2014, 28: 243-50.